480 related articles for article (PubMed ID: 20199137)
1. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.
Seino Y; Rasmussen MF; Nishida T; Kaku K
Curr Med Res Opin; 2010 May; 26(5):1013-22. PubMed ID: 20199137
[TBL] [Abstract][Full Text] [Related]
2. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.
Kaku K; Rasmussen MF; Clauson P; Seino Y
Diabetes Obes Metab; 2010 Apr; 12(4):341-7. PubMed ID: 20380655
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
4. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
Feinglos MN; Saad MF; Pi-Sunyer FX; An B; Santiago O;
Diabet Med; 2005 Aug; 22(8):1016-23. PubMed ID: 16026367
[TBL] [Abstract][Full Text] [Related]
5. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
[TBL] [Abstract][Full Text] [Related]
9. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.
Nauck M; Marre M
Postgrad Med; 2009 May; 121(3):5-15. PubMed ID: 19491535
[TBL] [Abstract][Full Text] [Related]
10. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Marre M; Shaw J; Brändle M; Bebakar WM; Kamaruddin NA; Strand J; Zdravkovic M; Le Thi TD; Colagiuri S;
Diabet Med; 2009 Mar; 26(3):268-78. PubMed ID: 19317822
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.
Garber A; Henry RR; Ratner R; Hale P; Chang CT; Bode B;
Diabetes Obes Metab; 2011 Apr; 13(4):348-56. PubMed ID: 21205128
[TBL] [Abstract][Full Text] [Related]
13. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.
Kesavadev J; Shankar A; Gopalakrishnan G; Jothydev S
Diabetes Metab Syndr; 2015; 9(1):30-3. PubMed ID: 25605673
[TBL] [Abstract][Full Text] [Related]
16. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
Davidson JA; McMorn SO; Waterhouse BR; Cobitz AR
Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
[TBL] [Abstract][Full Text] [Related]
18. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
Madsbad S; Schmitz O; Ranstam J; Jakobsen G; Matthews DR;
Diabetes Care; 2004 Jun; 27(6):1335-42. PubMed ID: 15161785
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
Kapitza C; Forst T; Coester HV; Poitiers F; Ruus P; Hincelin-Méry A
Diabetes Obes Metab; 2013 Jul; 15(7):642-9. PubMed ID: 23368510
[TBL] [Abstract][Full Text] [Related]
20. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
Kvapil M; Swatko A; Hilberg C; Shestakova M
Diabetes Obes Metab; 2006 Jan; 8(1):39-48. PubMed ID: 16367881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
